Phase 2 N=12 Podocyte Retinoids
Collapsing Glomerulopathy · Glomerulosclerosis, Focal Segmental
Primary: Change in Proteinuria at Week 24 From Baseline — 8.42; 7.67 g/g
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=16 Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
Kidney Diseases
Primary: 24 Hour Proteinuria — 3.6; 3.8; 2.2; 3.0 g/day
Phase 3 N=39 Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy
Glomerulonephritis, Membranous
Primary: Percentage of Complete Remission — 4; 3 Participants
N/A N=58 UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)
Idiopathic Nephrotic Syndrome
Primary: Number of Participants Reporting Medication Adherence — 25; 21; 19; 18 Participants
Phase 2 N=15 Permeability Factor in Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis
Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…
Phase 3 N=31 Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome
Nephrotic Syndrome
Primary: Number of Participants Experienced a Relapse of Nephrotic Syndrome — 14; 15 Participants
N/A N=7 Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
Focal Segmental Glomerulosclerosis · Steroid Resistant Nephrotic Syndrome
Primary: Focal Segmental Glomerulosclerosis Permeability Factor (FSPF) — 0.69; 0.35 Palb — p=0.009
Phase 4 N=77 Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children
Nephrotic Syndrome
Primary: Remission Rate — 34; 13 Participants — p=0.001
Phase 3 N=8 Steroid Treatment for Kidney Disease
Nephrosis · Focal Lipoid Glomerulosclerosis
Primary: Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks — 1; 1; 2; 1 participants — p=0.9074
Phase 4 N=15 Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)
Treatment Resistant Nephrotic Syndrome
Primary: Significant Reduction in Proteinuria to Remission Levels During the Treatment Period (Includes Complete and Partial Remission, as Defined in the Outcome Measure…
Phase 4 N=63 Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria
Idiopathic Focal Segmental Glomerulosclerosis
Primary: Number of Participants With Adverse Events — 0; 11; 60 Participants
Phase 4 N=40 Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis
Glomerulonephritis, Membranous
Primary: Number of Patient Who Gained Remission From the Nephrotic Syndrome — 8; 8 Participants — p=0.7
Phase 2 N=14 A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy
Glomerulonephritis, Membranous
Primary: Change From Baseline in Proteinuria Levels at Week 28 — 0.7552 Ratio
Phase 2 N=21 Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
Fibrosis · Focal Glomerulosclerosis · Kidney Failure
Primary: Decrease in GFR During Treatment Period — -0.45 ml/min/1.73 m2 — p=<0.01
Phase 4 N=60 Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
Proteinuria · Idiopathic Membranous Nephropathy
Primary: Percentage of Participants With Complete or Partial Remission in Proteinuria at 24 Weeks — 1; 5; 2; 0 Participants
Phase 2 N=7 Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
FSGS · MCD · Focal Segmental Glomerulosclerosis
Primary: Change in Urine MCP1/Cr Levels — 5.57; 2.89 ng/mg
Phase 2 N=36 Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
Nephrotic Syndrome · Focal Segmental Glomerulosclerosis · Minimal Change Disease
Primary: Percentage of Participants in Renal Response at Day 113 — 0.0; 7.7; 12.5; 33.3 Percent of Participants
Phase 4 N=34 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
IgA Nephropathy
Primary: Change in Proteinuria at 12 Months — 3; 3; 1; 2 participants
Phase 2 N=46 Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
IgA Nephropathy
Primary: MCP-Mod Estimates of the Ratio to Baseline of Urine Protein to Creatinine Ratio (UPCR) (g/Mol) - Parts 1 and 2 at Day 90 — 0.85; 0.80; 0.76; 0.69 Ratio to baseline…
Phase 4 N=52 Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease
Minimal Change Disease
Primary: Percentage of Participants Achieving Complete Remission From Nephrotic Syndrome at 8 Weeks — 21; 17 Participants — p=0.12
Phase 3 N=364 Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
Primary IgA Nephropathy
Primary: Part A: Ratio of Urine Protein to Creatinine Ratio (UPCR) at 9 Months Compared to Baseline — 0.69; 0.95 ratio — p=0.0003
Phase 3 N=371 Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis
Primary: Slope of Estimated Glomerular Filtration Rate (eGFR) — -5.4; -5.7 milliliters/minute/1.73square meter/year — p=0.7491
Phase 3 N=130 MEmbranous Nephropathy Trial Of Rituximab
Idiopathic Membranous Nephropathy
Primary: Remission Status — 39; 13 Participants — p=0.001
Phase 2 N=23 Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial
Focal Segmental Glomerulosclerosis
Primary: Number of Participants With a Reduction in Proteinuria at 6 Months by > 50% of the Value at Screening AND Stable GFR Defined as Greater Than 75 ml/Min/1.73m2 in Those…
Phase 2 N=67 A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis
Kidney Disease, Chronic
Primary: Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12 — 48.9; 16.0; 38.5; 11.4 Predicted percentage of…
Phase 4 N=5 Adrenocorticotropic Hormone in Membranous Nephropathy
Membranous Nephropathy
Primary: Change in Proteinuria — 4.56; 1.36 ratio
Phase 1 N=6 Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Dense Deposit Disease · Membranoproliferative Glomerulonephritis
Primary: Number of Patients With Change in Proteinuria or Serum Creatinine Over Treatment Period — 5 Participants
Phase 2 N=83 Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy
Diabetic Nephropathy
Primary: Ratio to Baseline in Urinary Albumin to Creatinine Ratio (UACR) — 0.90; 1.06; 0.83; 1.00 Ratio to baseline
Phase 3 N=144 A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
Lupus Nephritis
Primary: Percentage of Participants Who Achieved a Complete Renal Response (CRR), a Partial Renal Response (PRR), or no Renal Response (NRR) at Week 52 — 26.4; 30.6; 30.6; 15.3…
Phase 2 N=21 Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
IgA Nephropathy · Lupus Nephritis · Membranous Nephropathy
Primary: Part A: Change From Baseline in Proteinuria at Week 48 — -0.1364; 0.3560; 0.3430; -2.0347 ratio